Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 34th Annual Roth Conference.

Event	34th Annual Roth Conference
Date	March 15, 2022
Time	2:30 PM Pacific Time (5:30 PM Eastern Time)
Format	Fireside Chat
Link	https://wsw.com/webcast/roth43/nvct/1845484

About Nuvectis Pharma

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. The Company's pipeline includes NXP800, a clinical-stage HSF1-pathway inhibitor, and NXP900, a SRC/YES1 kinase inhibitor in IND-enabling pre-clinical testing.

For more information, please visit www.nuvectis.com.

Nuvectis Pharma Contact:

Ron Bentsur

Chairman, Chief Executive Officer and President

This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Relations Contact:

LifeSci Advisors on behalf of Nuvectis Pharma, Inc.

Eric Goldstein

Tel: 646-791-9729

This email address is being protected from spambots. You need JavaScript enabled to view it.